1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Bladder Cancer: Positive Signs For Tecentriq, Seattle Genetics Shines

 
• By Andrew McConaghie

Middling data for Roche’s IO plus chemo combo were presented at ESMO, while Seattle's rival drug antibody conjugate posted an impressive Phase I response rate.

ESMO
Barcelona plays host to Europe's leading cancer congress ESMO this year • Source: ESMO

When US and European regulators placed restrictions on the use of Roche’s Tecentriq and Merck & Co. Inc.’s Keytruda as monotherapies in bladder cancer last year, it signaled a very clear step back for the onward march of immunotherapies (IO) in the tumor type.

The Food and Drug Administration and the European Medicines Agency were responding to early analyses of two confirmatory Phase III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

Summit Presses Ahead With Ivonescimab Filing Despite Approval Doubts

 
• By Andrew McConaghie

Frontrunner believes it can gain a first approval in EGFR+ lung cancer, even though the FDA recently raised the bar on overall survival.

ESMO 25: IO Faces Difficult Pathway For Cylembio In Melanoma

 
• By Alaric DeArment

The company presented detailed data at ESMO and said its Phase III trial might have reached statistical significance with a larger sample size.

ESMO 25: Merck & Co Raises Hopes in Ovarian Cancer

 
• By Kevin Grogan

The company breaks new ground with Keytruda for platinum-resistant ovarian cancer and unveils promising Phase II data on its Daiichi-Sankyo-partnered ADC raludotatug deruxtecan.

ESMO 25: Akeso’s Ivonescimab Triumphs In 1L Squamous NSCLC, With Longest PFS In China Population

 
• By Dexter Jie Yan

Besting BeOne Medicines’ Tevimbra plus chemotherapy, interim results from the head-to-head HARMONi-6 study of Akeso's ivonescimab plus chemotherapy show the combo might have the longest PFS versus its single-target immuno-oncology competitors.

More from Anticancer

ESMO 25: Ovarian Cancer Data Validates Tubulis ADC Platform

 
• By Kevin Grogan

Positive first-in-human data for TUB-040 represent "a momentous milestone" for the German biotech, according to its CEO Dominik Schumacher.

ESMO 25: Biokin/SystImmune’s BsADC Doubles ORR/PFS Vs Chemo In NPC

 
• By Xu Hu

Biokin/SystImmune’s anti-EGFRxHER3 ADC iza-bren achieved one primary and the key secondary objectives in a Phase III trial in Chinese patients with R/M NPC and its lower incidence of interstitial lung disease compared with other ADCs is also noteworthy.

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO

 
• By Mandy Jackson

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.